ENDRA Life Sciences Inc. (NDRA)
| Market Cap | 6.45M +86.6% |
| Revenue (ttm) | n/a |
| Net Income | -7.30M |
| EPS | -7.71 |
| Shares Out | 1.24M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 15,061 |
| Open | 5.59 |
| Previous Close | 5.46 |
| Day's Range | 5.17 - 5.59 |
| 52-Week Range | 2.92 - 11.96 |
| Beta | -0.11 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 18, 2026 |
About NDRA
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source such as radio frequency to transmit energy deep into tissue and generate ultrasonic waves to create high-contrast images for use in the treatment of non-alcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion analysis. ENDRA Life Sciences Inc. ... [Read more]
Financial Performance
Financial StatementsNews
Endra Life Sciences reports Q1 EPS ($1.09) vs. ($1.86) last year
“During the first quarter, we continued to strengthen the clinical foundation for TAEUS Liver while maintaining disciplined operational execution,” said Alexander Tokman, CEO of ENDRA Life Sciences (N...
ENDRA Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASLD--ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring...
ENDRA Life Sciences Quarterly report: Q1 2026
ENDRA Life Sciences has published its Q1 2026 quarterly earnings report on May 15, 2026.
Endra Life Sciences reports multi-site validation of TAEUS Liver device
Endra Life Sciences (NDRA) announced multi-site clinical validation results for TAEUS Liver that demonstrate “strong” concordance with MRI-PDFF, high reproducibility and consistent performance across ...
ENDRA Life Sciences Reports Multi-Site Validation of TAEUS® Liver Device Demonstrating MRI-like Accuracy and Reproducibility
ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASLD--ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for the early detection and monito...
ENDRA Life Sciences Inc trading halted, volatility trading pause
15:38 EDT ENDRA Life Sciences (NDRA) Inc trading halted, volatility trading pause
ENDRA Life Sciences Inc trading resumes
15:43 EDT ENDRA Life Sciences (NDRA) Inc trading resumes
Endra Life Sciences reports Q4 EPS ($8.93) vs ($56.94) last year
“Over the past year we significantly strengthened the clinical foundation for TAEUS, demonstrating performance that we believe positions our technology alongside the current standard of care, while ma...
ENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASLD--ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring...
ENDRA Life Sciences Annual report: Q4 2025
ENDRA Life Sciences has published its Q4 2025 annual report on March 31, 2026.
ENDRA Life Sciences Earnings release: Q4 2025
ENDRA Life Sciences released its Q4 2025 earnings on March 31, 2026, summarizing the period's financial results.
Endra Life Sciences initiates review of strategic alternatives
ENDRA Life Sciences (NDRA)’ Board of Directors has initiated a process to evaluate a range of strategic alternatives aimed at maximizing shareholder value. As a part of this process, the…
ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value
ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASLD--ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring...
Endra Life Sciences announces favorable TAEUS liver device study results
Endra Life Sciences (NDRA) announced favorable results from a clinical study evaluating the measurement consistency of its TAEUS Liver device. “While MRI-PDFF remains the gold standard for liver fat q...
ENDRA's TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care
ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASLD--ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for the early detection and monito...
Endra Life Sciences announces results from Taeus Liver device feasibility study
Endra Life Sciences (NDRA) announced new results from its 2025 Taeus Liver device feasibility study demonstrating that Taeus’ thermo-acoustic fat fraction measurement closely tracks the MRI-PDFF stand...
ENDRA's TAEUS® Liver Matches MRI-PDFF Performance at Key Clinical Thresholds, Positioning Device for MASLD/MASH Trial Use
ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASH--ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermo-acoustic biomarker imaging for early detection and monitoring...
ENDRA Feasibility Study Demonstrates TAEUS® Accurately Quantifies Liver Fat Fraction, a Key MASLD/MASH Biomarker
ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASH--ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in biomarker imaging technologies for the early detection and monitorin...
ENDRA Life Sciences Recaps Major Milestones and New Strategic Initiatives, Announces Third Quarter 2025 Financial Results
ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASH--ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer in biomarker imaging technologies for the early detection and monitorin...
ENDRA Life Sciences Earnings release: Q3 2025
ENDRA Life Sciences released its Q3 2025 earnings on November 14, 2025, summarizing the period's financial results.
ENDRA Life Sciences Quarterly report: Q3 2025
ENDRA Life Sciences has published its Q3 2025 quarterly earnings report on November 14, 2025.
Endra Life Sciences commences staking of HYPE digital asset holdings
ENDRA Life Sciences (NDRA) announced it has commenced staking its holdings of HYPE (HYPE-USD), the native token of the Hyperliquid ecosystem. The company said the move is designed to maximize…
ENDRA Life Sciences Commences Staking of HYPE Digital Asset Holdings, Reinforcing Long-Term Strategy with Anchorage Digital and ARCA
ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASH--ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer in imaging technologies for the early detection and monitoring of metab...
Endra Life Sciences files to sell 2.68M shares of common stock for holders
The company will not receive any proceeds from the sale of shares by the selling stockholders.
ENDRA Life Sciences Registration statement: Registration Filing
ENDRA Life Sciences filed a registration statement on November 6, 2025, providing details about a securities offering with the SEC.